ストックスクリーナーアプリを入手
3.32
1.84%
0.06
アフターアワーズ：
3.31
-0.010
-0.30%
前日終値:
$3.26
開ける：
$3.28
24時間の取引高:
985.33K
Relative Volume:
0.61
時価総額：
$207.17M
収益：
$2.81M
当期純損益:
$-97.34M
株価収益率:
-1.8444
EPS:
-1.8
ネットキャッシュフロー:
$-91.47M
1週間 パフォーマンス:
+2.47%
1か月 パフォーマンス:
-13.09%
6か月 パフォーマンス:
-57.16%
1年 パフォーマンス:
-14.65%
1日の値動き範囲:
$3.21
$3.345
1週間の範囲:
$3.13
$3.38
52週間の値動き範囲:
$2.865
$13.70
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
| 2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 開始されました | Goldman | Buy |
| 2022-03-08 | 開始されました | Oppenheimer | Outperform |
| 2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-16 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
Vanguard Group Inc's Strategic Acquisition in Fulcrum Therapeuti - GuruFocus.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Hold" from Brokerages - MarketBeat
We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance
Ratios in Focus: Analyzing Fulcrum Therapeutics Inc (FULC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN
The FULC Stock Puzzle: Unraveling Fulcrum Therapeutics Inc’s Fluctuating Performance - The InvestChronicle
Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - SETE News
Further weakness as Fulcrum Therapeutics (NASDAQ:FULC) drops 12% this week, taking three-year losses to 88% - Simply Wall St
Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... - Yahoo Finance
Stock Traders Buy Large Volume of Call Options on Fulcrum Therapeutics (NASDAQ:FULC) - MarketBeat
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet? - Zacks Investment Research
Dimensional Fund Advisors LP Grows Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares - Yahoo Finance
Fulcrum Therapeutics Inc (FULC) stock on the rise: An overview - US Post News
Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) - MSN
Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround - MSN
An analyst sees good growth prospects for Fulcrum Therapeutics Inc (FULC) - SETE News
Daily Market Movement: Fulcrum Therapeutics Inc (FULC) Sees a 0.84 Increase, Closing at 3.60 - The Dwinnex
Biotech layoff tracker: 13 biotechs cut over 1,400 jobs - The Business Journals
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Consensus PT from Analysts - MarketBeat
Fulcrum Therapeutics' SWOT analysis: stock outlook shifts on trial results - Investing.com
Are Fulcrum Therapeutics Inc (FULC) shares a good deal now? - US Post News
FULC Stock on the Rise: A Promising Investment - The InvestChronicle
Fulcrum Therapeutics' SWOT analysis: stock outlook shifts on trial results By Investing.com - Investing.com Australia
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 41.4% in September - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - AccessWire
Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback - MSN
Fulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market Opportunity - MarketWatch
The Significance of Moving Averages in Fulcrum Therapeutics Inc Inc. (FULC) Price Performance - The InvestChronicle
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation - AccessWire
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Fulcrum Therapeutics announces workforce reduction - Investing.com India
Wall Street analysts’ outlook for Fulcrum Therapeutics Inc (FULC) - SETE News
Analysts review Fulcrum Therapeutics Inc’s rating - Knox Daily
Fulcrum Therapeutics announces workforce reduction By Investing.com - Investing.com Australia
Fulcrum Therapeutics to cut jobs after dystrophy drug failure - The Business Journals
Fulcrum reduces its workforce - MSN
Fulcrum Therapeutics to Cut 29 Jobs Amid Reprioritization of R&D - MarketWatch
Fulcrum Therapeutics Inc. (FULC) will reduce its workforce - StreetInsider.com
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - Benzinga
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation - AccessWire
Market Watch Highlights: Fulcrum Therapeutics Inc (FULC) Ends on an Downturn Note at 3.20 - The Dwinnex
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation! - AccessWire
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! - PR Newswire
Examining Fulcrum Therapeutics Inc (FULC) more closely is necessary - US Post News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - AccessWire
Bank of New York Mellon Corp Makes New $1.16 Million Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Largest borrow rate increases among liquid names - TipRanks
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):